Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 16Recruiting 11Terminated 10Active not recruiting 5Withdrawn 3Temporarily not available 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Non-Small-Cell Lung 298Neoplasms 179Breast Neoplasms 170Colorectal Neoplasms 107Neoplasm Metastasis 100Melanoma 99Multiple Myeloma 93Prostatic Neoplasms 90Ovarian Neoplasms 83Recurrence 80Carcinoma, Renal Cell 73Lung Neoplasms 71Stomach Neoplasms 67Squamous Cell Carcinoma of Head and Neck 67Lymphoma, Non-Hodgkin 61Pancreatic Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 56Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 48Triple Negative Breast Neoplasms 47Small Cell Lung Carcinoma 46Urinary Bladder Neoplasms 45Lymphoma, Large B-Cell, Diffuse 43Head and Neck Neoplasms 41Endometrial Neoplasms 41Lymphoma, Follicular 39Lymphoma 37Uterine Cervical Neoplasms 35Parkinson Disease 4, Autosomal Dominant Lewy Body 34Glioblastoma 34

Interventions

niraparib 2Prednisone 2Abiraterone Acetate 2gallium 68 PSMA-11 1Rosuvastatin Calcium 1Pluvicto 1Pioglitazone 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Prostatic Neoplasms, Castration-Resistant × Clear all
NCT02592317 2026-06-05

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.

Phase 1 Active not recruiting
23 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-06-05

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT07047118 2026-05-01

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Novartis

Phase 2 Active not recruiting
138 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡